Yang Ding

Pharmacologically Targeting DHODH-Dependent Pyrimidine Metabolism with HSA-Conjugated BRQ Suppresses Leukemogenesis

Background: Metabolic reprogramming is a hallmark of acute myeloid leukemia (AML) and provides a rich source of therapeutic vulnerabilities. Among these, de novo pyrimidine biosynthesis has emerged as an important metabolic dependency, yet its contribution to AML progression remains incompletely defined. DHODH, a rate-...